03:31 AM EDT, 04/04/2024 (MT Newswires) -- AbbVie ( ABBV ) said late Wednesday it expects its Q1 2024 per-share adjusted earnings to take a $0.08 hit from acquired in-process research and development and milestones expense of $164 million on a pre-tax basis.

The company expects Q1 adjusted EPS of $2.18 to $2.22, including the impact, according to a regulatory filing. Analysts surveyed by Capital IQ project $2.33 per share.

For 2024, AbbVie ( ABBV ) said it now expects adjusted EPS of $10.97 to $11.17, compared with its prior range of $11.05 to $11.25. Analysts polled by Capital IQ expect $11.24 per share.

Price: 177.48, Change: +0.15, Percent Change: +0.08